<DOC>
	<DOCNO>NCT02325518</DOCNO>
	<brief_summary>The purpose study evaluate AZORGA® Ophthalmic Suspension compare COSOPT® Ophthalmic Solution IOP-lowering efficacy subject open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Comparison Intraocular Pressure ( IOP ) -Lowering Efficacy Safety AZORGA® Ophthalmic Suspension COSOPT® Ophthalmic Solution</brief_title>
	<detailed_description>After screen examination , subject enrol study move observation period . During observation period , prostaglandin-analog ( PGA ) monotherapy apply . After observation period 4 week , baseline examination perform . Subjects randomize moved treatment period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Understand nature study sign inform consent . Diagnosis open angle glaucoma ocular hypertension . Currently PGA monotherapy PGA + alpha1/beta blocker PGA + alpha2 agonist screen visit , allow instill PGA 4 week baseline visit . Intraocular pressure ( IOP ) ≥ 15 mmHg ( least one eye ) baseline visit . Other protocolspecified inclusion criterion may apply . History bronchial asthma , bronchospasm , serious chronic obstruction pulmonary disease . Uncontrolled heart failure , sinus bradycardia , AV block ( II , III grade ) , cardiogenic shock , right heart failure due pulmonary hypertension congestive heart failure . History hypersensitivity excipients study medication . Severe renal function disorder , diabetic ketoacidosis metabolic acidosis , uncontrolled diabetes , hepatic disorder . Corneal disorder history chronic , recurrent current severe inflammatory eye disease either eye . History ocular trauma either eye within 6 month prior screen examination . Ocular infection ocular inflammation either eye . History current clinically significant progressive retinal disease either eye . Intraocular surgery either eye within 6 month prior screen examination . Ocular laser surgery either eye within 3 month prior screen examination . Any abnormality prevent reliable applanation tonometry either eye . Bestcorrected visual acuity ( BCVA ) worse 0.2 score ( decimal visual acuity ) either eye . Severe visual field loss either eye . Use prohibit medication , specify protocol . Pregnant , lactating , intend become pregnant study period . Currently therapy therapy another investigational agent within 30 day prior screen examination . History current evidence severe illness condition would make subject , opinion investigator , unsuitable study . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Open-angle glaucoma ( OAG )</keyword>
	<keyword>Ocular hypertension ( OHT )</keyword>
	<keyword>AZORGA®</keyword>
	<keyword>COSOPT®</keyword>
</DOC>